drugset
drugset / Trial / NCT05489328

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

NCT05489328 ↗

Phase 1 Completed 394 enrolled Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.

Timeline

Start
2022-08-15
Primary completion
2022-10-07
Completion
2022-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Prevnar 13 Vaccine — Other
Subject V114 Vaccine — Other

Indications

pneumococcal infection